{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:32:45Z","timestamp":1766485965375,"version":"3.37.3"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>The aim of the present retrospective observational study was to evaluate the change of Renal Resistive Index (RRI) over time (\u0394RRI) and under treatment in patients with systemic sclerosis (SSc) as well as to correlate these changes with disease complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Two hundred thirty patients [29 male, median age 57 (IQR 48\u201367) yrs] were enrolled. At baseline and follow-up (3.43, IQR 2.81\u20134.45 yrs), we collected the following data: disease variables, nailfold videocapillaroscopy (NVC) pattern, forced vital capacity (FVC), diffusing lung capacity for carbon monoxide (DLCO), systolic pulmonary arterial pressure (sPAP), presence of interstitial lung disease, RRI, evaluation of glomerular filtration rate, and new onset of pulmonary arterial hypertension (PAH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>RRI value is high in SSc patients with digital ulcers and anticentromere antibodies, active and late NVC patterns, and limited cutaneous SSc. A significant correlation was observed between \u0394RRI and \u0394sPAP (R = 0.17, <jats:italic>P<\/jats:italic> = 0.02), with statistically higher \u0394RRI (0.08 \u00b1 0.02 vs 0.03 \u00b1 0.05, <jats:italic>P<\/jats:italic> = 0.04) in patients complicated by PAH onset. No other new-onset complication was associated with \u0394RRI. The receiver-operating characteristic curve analysis confirmed the predictive role of \u0394RRI in development of new PAH (area under the curve 0.84, 95% CI 0.75\u20130.93, <jats:italic>P<\/jats:italic> = 0.02). In patients with SSc never exposed to sildenafil, \u0394RRI was higher (0.04 \u00b1 0.05) compared to both patients exposed to sildenafil during the study period (0.01 \u00b1 0.05, <jats:italic>P<\/jats:italic> = 0.03) or in those exposed at the time of baseline evaluation (0.00 \u00b1 0.05, <jats:italic>P<\/jats:italic> = 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>RRI and its variation in time are a reliable marker of SSc-related vasculopathy, both in renal and extrarenal compartments.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.191101","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T16:15:20Z","timestamp":1585757720000},"page":"241-246","source":"Crossref","is-referenced-by-count":8,"title":["The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis"],"prefix":"10.3899","volume":"48","author":[{"given":"Antonietta","family":"Gigante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Lepri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Tesei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Maestripieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Moggi-Pignone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Melchiorre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Boddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bellando-Randone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-8093","authenticated-orcid":false,"given":"Edoardo","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"2022062114101481000_48.2.241.1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Rel Disord"},{"key":"2022062114101481000_48.2.241.2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2397198318758607","article-title":"Kidney involvement in Systemic Sclerosis: from pathogenesis to treatment","volume":"3","author":"Bruni","year":"2018","journal-title":"J Scleroderma Rel Disord"},{"key":"2022062114101481000_48.2.241.3","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.180.4.1800885"},{"key":"2022062114101481000_48.2.241.4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10157-016-1323-3","article-title":"Renal Resistive Index: not only kidney","volume":"21","author":"Di Nicol\u00f2","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"2022062114101481000_48.2.241.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102083440603"},{"key":"2022062114101481000_48.2.241.6","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.723748"},{"key":"2022062114101481000_48.2.241.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22309"},{"key":"2022062114101481000_48.2.241.8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5414\/CN108580","article-title":"Evaluation of estimated glomerular filtration rate and clinical variables in systemic sclerosis patients","volume":"85","author":"Gigante","year":"2016","journal-title":"Clin Nephrol"},{"key":"2022062114101481000_48.2.241.9","doi-asserted-by":"publisher","DOI":"10.1177\/0394632016645590"},{"key":"2022062114101481000_48.2.241.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.06.006"},{"key":"2022062114101481000_48.2.241.11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp121"},{"key":"2022062114101481000_48.2.241.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310311"},{"key":"2022062114101481000_48.2.241.13","first-page":"30314","article-title":"The Renal Resistive Index in systemic sclerosis: determinants, prognostic implication and proposal for specific age-adjusted cut-offs","volume":"S0953","author":"Bruni","year":"2019","journal-title":"Eur J Intern Med."},{"key":"2022062114101481000_48.2.241.14","doi-asserted-by":"crossref","unstructured":"Shanmugam VK , Steen VD. Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010;pii:538589.","DOI":"10.1155\/2010\/538589"},{"key":"2022062114101481000_48.2.241.15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-89-6-881","article-title":"The kidney in progressive systemic sclerosis: a prospective study","volume":"89","author":"Kovalchik","year":"1978","journal-title":"Ann Intern Med"},{"key":"2022062114101481000_48.2.241.16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000489740","article-title":"Prognostic Factors of Renal Involvement in Systemic Sclerosis","volume":"43","author":"Rosato","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2022062114101481000_48.2.241.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2022062114101481000_48.2.241.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136929"},{"key":"2022062114101481000_48.2.241.19","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2022062114101481000_48.2.241.20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5301\/jsrd.5000236","article-title":"Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition","volume":"2","author":"Suliman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2022062114101481000_48.2.241.21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Rel Disord"},{"key":"2022062114101481000_48.2.241.22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fphar.2019.00360","article-title":"Innovations in the Assessment of Primary and Secondary Raynaud\u2019s Phenomenon","volume":"10","author":"Ruaro","year":"2019","journal-title":"Front Pharmacol"},{"key":"2022062114101481000_48.2.241.23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034505"},{"key":"2022062114101481000_48.2.241.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2010.05.010"},{"key":"2022062114101481000_48.2.241.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2022062114101481000_48.2.241.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes049"},{"key":"2022062114101481000_48.2.241.27","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0056-2017"},{"key":"2022062114101481000_48.2.241.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.37988"},{"key":"2022062114101481000_48.2.241.29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000487198","article-title":"Presence of kidney disease as an outcome predictor in patients with pulmonary arterial hypertension","volume":"47","author":"Bitker","year":"2018","journal-title":"Am J Nephrol"},{"key":"2022062114101481000_48.2.241.30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000487199","article-title":"Pulmonary Arterial Hypertension and the Kidney: Getting to the Heart of the Matter","volume":"47","author":"Kazory","year":"2018","journal-title":"Am J Nephrol"},{"key":"2022062114101481000_48.2.241.31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11739-015-1289-2","article-title":"The internist and the renal resistive index: truths and doubts","volume":"10","author":"Boddi","year":"2015","journal-title":"Intern Emerg Med"},{"key":"2022062114101481000_48.2.241.32","first-page":"1944","article-title":"Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis","volume":"24","author":"Scorza","year":"1997","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.191101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:11:24Z","timestamp":1655845884000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.191101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.3899\/jrheum.191101"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.191101","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}